Sava Infond d.o.o. Has $1.90 Million Stake in Zoetis Inc. $ZTS

Sava Infond d.o.o. grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 11.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,150 shares of the company’s stock after acquiring an additional 1,200 shares during the quarter. Sava Infond d.o.o.’s holdings in Zoetis were worth $1,895,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Nova Wealth Management Inc. acquired a new position in Zoetis during the first quarter worth about $25,000. 1248 Management LLC acquired a new position in Zoetis during the first quarter worth about $27,000. Saudi Central Bank acquired a new position in Zoetis during the first quarter worth about $29,000. Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after acquiring an additional 88 shares in the last quarter. Finally, ORG Partners LLC raised its stake in Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after acquiring an additional 84 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ZTS shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Saturday, September 27th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Stock Performance

Shares of ZTS stock opened at $146.45 on Friday. The stock has a market capitalization of $64.91 billion, a PE ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. The business’s 50 day simple moving average is $149.79 and its 200 day simple moving average is $155.14. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a one year low of $139.34 and a one year high of $196.55.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.